Dom Esposito
@domespo.bsky.social
Protein biochemist, lover of pizza, mediocre golfer, even more mediocre poker player...
After many years of hard work by my colleagues at the Frederick National Laboratory and Bridge Bio Oncology Therapeutics, we finally have our first drug developed at the NCI RAS Initiaiive in clinical trials against KRAS--the driver of some very bad cancers. Details published this week:
Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C
Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...
aacrjournals.org
December 10, 2024 at 5:45 PM
After many years of hard work by my colleagues at the Frederick National Laboratory and Bridge Bio Oncology Therapeutics, we finally have our first drug developed at the NCI RAS Initiaiive in clinical trials against KRAS--the driver of some very bad cancers. Details published this week: